IIRC, MABs aren't really a thing, because unlike small molecules, part of the approval is for the whole biological pipeline to produce the antibodies, from cell line to chromatography to formulation. When a small molecule goes off patent, you just have to prove to the FDA you can make that molecule to sufficient purity.

That's not to say there are no generic MABs, it's that it is a far costlier process for the generic manufacturers to get up and running.

I wasn’t aware of this, thanks for clarification. I will leave my comment as-is because it’s my take on the general “we need to ban price gouging on new drugs!” sentiment.

What's the Mexican name? Asking for a Mexican friend.